


AMENDMENTS TO THE CLAIMS

This listing of claims replaces any prior version of the claims in the application.

5 Claims 1-32 (cancelled)

33 (withdrawn): A pharmaceutical composition comprising at least one compound of the following structure



10 wherein R⁵ and R⁶ are each independently selected from the group consisting of OC(O)OCH₃, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, provided that at least one of R⁷ and R⁸ are OC(O)OCH₃;

15

20

 wherein R⁷, R⁸, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are each independently selected from the group consisting of -H, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether,

an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one each of R^{12}

and R^{13} or R^{18} and R^{19} can independently be H;


wherein R^{24} and R^{25} are either H or CH_3 ;

wherein the dotted line is an optional double bond;

wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration;

and a pharmaceutically acceptable excipient.

34 (withdrawn): The pharmaceutical composition of claim 33, wherein said at least one compound has the following structure




wherein R^7 , R^8 , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are each independently selected from the group consisting of $-H$, $-OH$, $-SH$, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally

substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a
5 nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one each of R^{12} and R^{13} or R^{18} and R^{19} can independently be H;

10 wherein R^{24} and R^{25} are either H or CH_3 ;
wherein the dotted line is an optional double bond;
wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.


15 35 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure



wherein R^7 , R^8 , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} and R^{17} are each independently selected from the group consisting of -H, -OH, -SH, - NH_2 , - OSO_3H , - OPO_3H , an ester, a
20 phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle,

an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, and R^{16} and R^{17} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one of each of R^{12} and R^{13} can independently be H; wherein R^{24} and R^{25} are either H or CH_3 ; wherein the dotted line is an optional double bond; wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.

36 (withdrawn): The pharmaceutical composition of claim 35, wherein said at least one compound has the following structure



wherein R^{12} and R^{13} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^{12} and R^{13} together form a double


bond to a moiety selected from the group consisting of =O, =S, =CH₂ and =NOH, provided that only one of R¹² and R¹³ is H;

wherein R²⁴ and R²⁵ are either H or CH₃;

wherein the dotted line is an optional double bond;

- 5 wherein the OC(O)OCH₃ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.

37 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure




10 wherein R⁷, R⁸, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are each independently selected from the group consisting of -H, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl
15 group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a
20 nucleoside, a nucleotide, an oligonucleotide, a polymer and R⁷ and R⁸ together, R¹⁴ and R¹⁵ together, R¹⁶ and R¹⁷ together, and R¹⁸ and R¹⁹ together independently form a double bond to a moiety selected from the group consisting of =O, =S, =CH₂ and =NOH, provided that only one of each of R¹⁸ and R¹⁹ can be H;

wherein R^{24} and R^{25} are either H or CH_3 ;
wherein the dotted line is an optional double bond;
wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β
configuration; and a pharmaceutically acceptable excipient.

5

38 (withdrawn): The pharmaceutical composition of claim 37, wherein said
at least one compound has the following structure




wherein R^{18} and R^{19} are each independently selected from the group
10 consisting of -H, -OH, -SH, - NH_2 , - OSO_3H , - OPO_3H , an ester, a phosphoester, a
phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a
sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a
carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an
optionally substituted alkenyl group, an optionally substituted alkynyl group, an
15 optionally substituted aryl moiety, an optionally substituted heterocycle, an
optionally substituted heteroaryl moiety, an optionally substituted
monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a
nucleotide, an oligonucleotide, a polymer and R^{18} and R^{19} together form a double
bond to a moiety selected from the group consisting of =O, =S, = CH_2 and =NOH,
20 provided that only one of R^{18} and R^{19} is -H;

wherein R^{24} and R^{25} are either H or CH_3 ;
wherein the dotted line is an optional double bond;
wherein the - $OC(O)OCH_3$ at the 3 position is in either the α or β
configuration; and a pharmaceutically acceptable excipient.

25

39 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure




and a pharmaceutically acceptable excipient.

5

Claims 40-69 (cancelled)

Claim 70 (new): A method to treat a condition selected from the group consisting of androgen responsive prostate cancer and androgen responsive benign prostatic hyperplasia in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues an effective amount of a compound having the structure

10



wherein,

15

R^5 is -OH or a carbonate;

R^6 is -H

R^{12} and R^{13} independently or together are -H, -OH, an ester, an ether or =O;

or R^{16} and R^{17} independently or together are -H, -OH, an ester, an ether

20

or =O;

R^{18} is -OH, an ester or an ether;

R^{19} is -H, an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group;


5

R^{25} is optionally substituted alkyl.

Claim 71 (new): The method of claim 70, wherein the condition is androgen responsive prostate cancer.

10

Claim 72 (new): The method of claim 71 wherein the compound has the structure



wherein,

15

R^{18} is -OH; R^{19} is -H or R^{18} and R^{19} together are =O; R^6 is -H

R_5 is -OC(O)-O-CH₃ or -OC(O)-O-(CH₂)_m-(CF₂)_n-CH₃, wherein m=1,2,3,4,5, or 6 and n=0; R^{16} and R^{17} are -H;

(1) R^{12} and R^{13} together are =O, or

(2) R^{12} is -H and R^{13} is -OH, or

20

(3) R^{12} is -OH and R^{13} is -H, or

R^5 is -OH; R^{12} and R^{13} are -H;

(1) R^{16} and R^{17} together are =O

(2) R^{16} is -H and R^{17} is -OH, or

(3) R^{16} is -OH and R^{17} is -H, or

R^{18} is -OH; R^{19} is $-C\equiv CH$ or $-C\equiv CCH_3$;

R^5 is -OH;

5 (1) R^{12} and R^{13} are -H; R^{16} is -OH and R^{17} is -H, or


(2) R^{12} and R^{13} are -H; R^{16} is -H and R^{17} is -OH, or

(3) R^{12} and R^{13} are -H; R^{16} and R^{17} together are =O,

Claim 73 (new): The method of claim 72 wherein R^5 is $-OC(O)-O-CH_3$.

10

Claim 74 (new): The method of claim 73 wherein the compound has the structure



15

20